Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 9/20 | 0.53 |
| ▸ | ADAMTS4 | O75173 | 7/20 | 0.42 |
| ▸ | ADAMTS5 | Q9UNA0 | 7/20 | 0.42 |
| ▸ | MMP2 | P08253 | 6/20 | 0.42 |
| ▸ | MMP3 | P08254 | 6/20 | 0.42 |
| ▸ | MMP13 | P45452 | 6/20 | 0.42 |
| ▸ | MMP14 | P50281 | 6/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 4/20 | 0.42 |
| ▸ | MMP9 | P14780 | 3/20 | 0.42 |
| ▸ | MMP1 | P03956 | 2/20 | 0.42 |
| ▸ | MMP7 | P09237 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7944780 | 0.90 | NPC1 (0.46) | BACE1MMP2MMP13 | |
| SCHEMBL7941811 | 0.89 | MAPT (0.50) | BACE1 | |
| SCHEMBL7946595 | 0.89 | BACE1 (0.47) | BACE1PTGDR2 | |
| SCHEMBL7941917 | 0.86 | BACE1 (0.70) | BACE1 | |
| SCHEMBL7944995 | 0.85 | BACE1 (0.56) | BACE1 | |
| SCHEMBL12445873 | 0.85 | ADAMTS4 (0.44) | BACE1ADAMTS4ADAMTS5MMP2MMP3 | |
| SCHEMBL7944668 | 0.85 | BACE1 (0.51) | BACE1L3MBTL1PTGDR2 | |
| SCHEMBL12303332 | 0.84 | BACE1 (0.59) | BACE1 | |
| SCHEMBL7946590 | 0.84 | BACE1 (0.56) | BACE1L3MBTL1 | |
| SCHEMBL12303324 | 0.83 | BACE1 (0.74) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237576-A1 | 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| WO-2010047372-A1 | 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY | 塩野義製薬株式会社 (JP) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237576-A1 | 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY | BACE1, APP, BACE2 | BACE1 1/4885ADAMTS4 2523/4885ADAMTS5 2199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.